Ardelyx’s Ibsrela (tenapanor) Receives the US FDA’s Approval for Irritable Bowel Syndrome with Constipation (ISB-C) for Adults

 Ardelyx’s Ibsrela (tenapanor) Receives the US FDA’s Approval for Irritable Bowel Syndrome with Constipation (ISB-C) for Adults

Ardelyx’s Ibsrela (tenapanor) Receives the US FDA’s Approval for Irritable Bowel Syndrome with Constipation (ISB-C) for Adults

Shots:

  • The approval is based on P-III IBS-C program includes Trial 1 (NCT02686138) and Trial 2 (NCT02621892) which involve assessing of Ibsrela vs PBO in patients with abdominal pain and bowel movement frequency
  • The P-III IBS-C program met all 1EPs including Trial 1 and 2 (37%, 27% vs 24%, 19%), discontinuation rates (7.6% vs 0.8%)
  • Ibsrela (50 mg, bid) is an orally administered drug involves inhibiting of sodium/hydrogen exchanger 3 (NHE3) targeted for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults

Click here to­ read full press release/ article | Ref: Ardelyx | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post